Literature DB >> 31542240

Current practices and barriers to referral for cytoreductive surgery and HIPEC among colorectal surgeons: A binational survey.

Javariah Siddiqui1, Kilian Brown1, Assad Zahid1, Christopher John Young2.   

Abstract

INTRODUCTION: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has gained traction for the management of peritoneal metastases. The number of specialist units globally offering CRS/HIPEC is increasing. The aim of this survey was to assess current practices and barriers to referral for CRS/HIPEC among colorectal surgeons in Australia and New Zealand (ANZ).
MATERIALS AND METHODS: An online questionnaire was emailed to members of the Colorectal Surgical Society of Australia and New Zealand (CSSANZ). The survey contained 3 sections: namely; demographics, referral patterns and clinical scenarios. Questions on referral patterns included number of peritoneal metastases patients seen per year and referred to a CRS/HIPEC unit, awareness of such a unit and distance from principle place of practice. Different pathologies referred were also explored, as well as investigations performed. Barriers to referral were also surveyed.
RESULTS: The response rate was 28% (83/296). Twenty-five percent received CRS training. Most surgeons (95%) were aware of a CRS/HIPEC unit and had referred to one previously. Thirty-nine percent would refer all patients. Provision of good service and/or relationship with CRS/HIPEC specialist were the main reasons for referring to the nearest unit, followed by accessibility. Major factors preventing referral included extent of peritoneal disease (48%), patient characteristics and comorbidities (44%) and lack of evidence (20%). The most common pathologies referred included colorectal and appendiceal peritoneal metastases and pseudomyxoma peritonei.
CONCLUSION: Colorectal specialist awareness of CRS/HIPEC units and accessibility is high. Strategies to improve referring physician/surgeon knowledge on patient selection and indications for CRS/HIPEC should be investigated and instituted to ensure all appropriate patients are referred to specialist units for discussion of suitability.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Barriers to referral; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal metastases; Survey

Year:  2019        PMID: 31542240     DOI: 10.1016/j.ejso.2019.09.007

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

1.  A Consensus-Based Checklist for Reporting of Survey Studies (CROSS).

Authors:  Akash Sharma; Nguyen Tran Minh Duc; Tai Luu Lam Thang; Nguyen Hai Nam; Sze Jia Ng; Kirellos Said Abbas; Nguyen Tien Huy; Ana Marušić; Christine L Paul; Janette Kwok; Juntra Karbwang; Chiara de Waure; Frances J Drummond; Yoshiyuki Kizawa; Erik Taal; Joeri Vermeulen; Gillian H M Lee; Adam Gyedu; Kien Gia To; Martin L Verra; Évelyne M Jacqz-Aigrain; Wouter K G Leclercq; Simo T Salminen; Cathy Donald Sherbourne; Barbara Mintzes; Sergi Lozano; Ulrich S Tran; Mitsuaki Matsui; Mohammad Karamouzian
Journal:  J Gen Intern Med       Date:  2021-04-22       Impact factor: 6.473

2.  Current Opinion and Practice on Peritoneal Carcinomatosis Management: The North African Perspective.

Authors:  Amine Souadka; Hajar Essangri; Amin Makni; Mourad Abid; Mouna Ayadi; Feriel Ksantini; Zakia Kordjani; Yousri Ballah; Jemila Bouka; Amine Benkabbou; Mohammed Anass Majbar; Basma El Khannoussi; Raouf Mohsine; Saber Boutayeb; Martin Hubner
Journal:  Front Surg       Date:  2022-03-08

3.  The attitude and practice of general surgeons toward cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A cross-sectional study.

Authors:  Thamer A Bin Traiki; Sulaiman A AlShammari; Wadha S AlOtaibi; Shahad N AlAnazi; Mashal M Alnmry; Abdullah M Albdah; Noura S Alhassan
Journal:  Ann Med Surg (Lond)       Date:  2021-06-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.